Other income, net increased $4.5 million to $5.6 million for the three-month period ended December 31, 2012, from $1.1 million for the three-month period ended December 31, 2011. This increase is primarily due to a non-cash gain of $5.1 million during the three-month period ended December 31, 2012 relating to the mark-to-market valuation adjustment of our warrant liability.
CONFERENCE CALL AND WEBCAST
The Company will host a live conference call and webcast on March 19, 2013, at 9:00 a.m. Eastern Time to discuss these results and to answer questions. To participate by telephone, please dial:Domestic:
99134844The live and archived webcast can be accessed via the investor relations section of the Savient website at www.savient.com. A telephone replay will be available through March 25, 2013, by dialing:
99134844ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients who do not respond to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP"). Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and c
|SOURCE Savient Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved